Immunosuppression in HCV-positive liver-transplant recipients

Current Opinion in Organ Transplantation

Volumn 17, Issue 6, 2012, Pages 648-654

  Chan, Aaron James ^a   Lake, John R ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

HCV; hepatitis C; immunosuppression; liver; transplant

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; TEMSIROLIMUS; THYMOCYTE ANTIBODY;

CORTICOSTEROID THERAPY; DISEASE COURSE; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFECT; GRAFT SURVIVAL; HEPATITIS C; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); POST TREATMENT SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTILYMPHOCYTE SERUM; AZATHIOPRINE; CALCINEURIN; CLINICAL TRIALS AS TOPIC; CYCLOSPORINE; HEPATITIS C; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; LIVER TRANSPLANTATION; MYCOPHENOLIC ACID; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; SIROLIMUS; TACROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84870243570     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32835a2b5a     Document Type: Review

References (72)

1. World Health Organization. Factsheet 164 hepatitis C. Geneva: WHO; 2012.
2. Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis 2012; 55 (Suppl 1):S10-S15.
3. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14 (Suppl 2):S36-S44.
4. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2010 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2011.
5. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122:889-896. (Pubitemid 34267271)
6. John PR, Thuluvath PJ. Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl 2002; 8:708-713.
7. Steinmuller TH, Stockmann M, Bechstein WO, et al. Liver transplantation and diabetes mellitus. Exp Clin Endocrinol Diabetes 2000; 108:401-405.
8. Cosio FG, Pesavento TE, Kim S, et al. Patient survival after renal transplantation: IV. Impact of posttransplant diabetes. Kidney Int 2002; 62:1440-1446.
9. Fernandez-Fresnedo G, Escallada R, de Francisco AL, et al. Posttransplant diabetes is a cardiovascular risk factor in renal transplant patients. Transplant Proc 2003; 35:700-703.
10. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3:178-185. (Pubitemid 36323115)
11. Miles AM, Sumrani N, Horowitz R, et al. Diabetes mellitus after renal transplantation: as deleterious as non transplant-associated diabetes? Transplantation 1998; 65:380-384. (Pubitemid 28095966)
12. Revanur VK, Jardine AG, Kingsmore DB, et al. Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant 2001; 15:89-94. (Pubitemid 32229796)
13. Ciesek S, Wedemeyer H. Immunosuppression, liver injury and posttransplant HCV recurrence. J Viral Hepat 2012; 19:1-8.
14. Berenguer M, Prieto M, Palau A, et al. Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis. Liver Transpl 2003; 9:228-235. (Pubitemid 36322323)
15. Charlton M. Patient and graft survival following liver transplantation for hepatitis C: much ado about something. Gastroenterology 2002; 122: 1162-1165. (Pubitemid 34267298)
16. Weir MR, Fink JC. Risk for posttransplant Diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 1999; 34:1-13. (Pubitemid 29318789)
17. Mukherjee S, Mukherjee U. A comprehensive review of immunosuppression used for liver transplantation. J Transplant 2009; 2009:1-20.
18. National Institutes of Health. Liver Transplantation. National Institute of Health Consensus Development Conference Summary. 1983; Washington, DC: National Institute of Health Consensus Development; 1983. p.15.
19. Gordon RD, Shaw BW Jr, Iwatsuki S, et al. Indications for liver transplant in cyclosporine era. Surg Clin North Am 1986; 66:541-556. (Pubitemid 16057677)
20. Post DJ, Douglas DD, Mulligan DC. Immunosuppression in liver transplantation. Liver Transpl 2005; 11:1307-1314. (Pubitemid 43071575)
21. Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004; 4:583-595. (Pubitemid 38523581)
22. McAlister VC, Haddad E, Renouf E, et al. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 2006; 6:1578-1585. (Pubitemid 43945797)
23. Zervos XA, Weppler D, Fragulidis GP, et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation 1998; 65:1044-1046. (Pubitemid 28208421)
24. Gonzalez MG, Madrazo CP, Rodriguez AB, et al. An open, randomized, multicenter clinical trial of oral tacrolimus in liver allograft transplantation: a comparison of dual vs. triple drug therapy. Liver Transpl 2005; 11:515-524.
25. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331:1110-1115.
26. Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007; 13:21-29. (Pubitemid 46099970)
27. Trotter JF. Hot-topic debate on hepatitis C virus: the type of immunosuppression matters. Liver Transpl 2011; 17 (Suppl 3):S20-S23.
28. O'Grady JG, Hardy P, Burroughs AK, et al. Randomized controlled trial of tacrolimus versus microemulsified cyclosporine (TMC) in liver transplantation: poststudy surveillance to 3 years. Am J Transplant 2007; 7:137-141. (Pubitemid 44952866)
29. Fisher RA, Stone JJ, Wolfe LG, et al. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation. Clin Transplant 2004; 18:463-472. (Pubitemid 39077084)
30. Berenguer M, Aguilera V, San Juan F, et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. Transplantation 2010; 90:1204-1209.
31. Irish WD, Arcona S, Bowers D, Trotter JF. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. Am J Transplant 2011; 11:1676-1685.
32. Forns X, Navasa M. Cyclosporine A or tacrolimus for hepatitis C recurrence? An old debate. Am J Transplant 2011; 11:1559-1560.
33. Sheiner PA, Schwartz ME, Mor E, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21:30-34.
34. Carrion JA, Navasa M, Garcia-Pagan JC, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132:1746-1756. (Pubitemid 46695723)
35. Berenguer M, Aguilera V, Prieto M, et al. Effects of calcineurin inhibitors on survival and histological disease severity in HCV-infected liver transplant recipients. Liver Transpl 2006; 12:762-767.
36. Martin P, Busuttil RW, Goldstein RM, et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl 2004; 10:1258-1262. (Pubitemid 39406080)
37. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334:815-820. (Pubitemid 26099603)
38. Watashi K, Hijikata M, Hosaka M, et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38:1282-1288. (Pubitemid 37314838)
39. Henry SD, Metselaar HJ, Lonsdale CB, et al. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporine A and interferon-a. Gastroenterology 2006; 12:1452-1462. (Pubitemid 44708933)
40. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32:673-684. (Pubitemid 30180389)
41. Neumann UP, Berg T, Bahra M, et al. Longer-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004; 77:226-231. (Pubitemid 38155751)
42. Weiler N, Thrun I, Hoppe-Lotichius M, et al. Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial. Transplantation 2010; 90:1562-1566.
43. Marubashi S, Dono K, Nagano J, et al. Steroid-free living donor liver transplantation in adults: impact on hepatitis C recurrence. Clin Transplant 2009; 22:892-905.
44. Sgourakis G, Radtke A, Fouzas I, et al. Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes. Transpl Int 2009; 22:892-905.
45. Wiesner RH, Sorrell M. Villamil F; for International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society Expert Panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9:S1-S9. (Pubitemid 37407996)
46. Samuel D, Forns X, Berenguer M, et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol 2006; 45:127-143. (Pubitemid 43850627)
47. Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 2003; 9:S63-S66. (Pubitemid 37408006)
48. Kato T, Gaynor JJ, Yoshida H, et al. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation 2007; 84:829-835. (Pubitemid 351338942)
49. Kato T, Yoshida H, Sadfar K, et al. Steroid-free and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study. Transplant Proc 2005; 37:1217-1219. (Pubitemid 40590841)
50. Lladó L, Fabregat J, Castellote J, et al. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transpl 2008; 14:1752-1760.
51. Manousou P, Samonakis D, Cholongitas E, et al. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transpl 2009; 15:1783-1791.
52. + liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007; 13:1521-1531. (Pubitemid 350168192)
53. Klintmalm GB, Davis GL, Teperman L, et al. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl 2011; 17:1394-1403.
54. Neumann U, Samuel D, Trunečka P, et al. A randomized multicenter study comparing a tacrolimus-based protocol with and without steroids in HCV-positive liver allograft recipients. J Transplant 2012; 2012:1-9.
55. Brillanti S, Vivarelli M, De Ruvo N, et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002; 8:884-888. (Pubitemid 35154016)
56. Vivarelli M, Burra P, Barba GL, et al. Influence of steroids on HCV recurrence after liver transplantation: a prospective study. J Hepatol 2007; 47:793-798. (Pubitemid 350051119)
57. Schlitt HJ, Barkmann A, Boker KH, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomized controlled study. Lancet 2001; 357:587-591. (Pubitemid 32179611)
58. Stewart SF, Hudson M, Talbot D, et al. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001; 357:609-610. (Pubitemid 32179620)
59. Wiesner R, Rabkin J, Klintmalm G, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7:442-450. (Pubitemid 32492583)
60. Jain A, Kashyap R, Demetris AJ, et al. A prospective randomized trial of cycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002; 8:40-46. (Pubitemid 34092671)
61. Wiesner RH, Shorr JS, Steffen BJ, et al. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 2005; 11:750-759. (Pubitemid 40975576)
62. Asthana S, Toso C, Meeberg G, et al. The impact of sirolimus on hepatitis C recurrence after liver transplantation. Can J Gastroenterol 2011; 25:28-34.
63. McKenna GJ, Trotter JF, Klintmalm N, et al. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am J Transplant 2011; 11:2379-2387.
64. Eason JD, Loss GE, Blazek J, et al. Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial. Liver Transpl 2001; 7:693-697. (Pubitemid 32771467)
65. Eason JD, Nair S, Cohen AJ, et al. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003; 75:1396-1399. (Pubitemid 36513055)
66. Tector AJ, Fridell JA, Mangus RS, et al. Promising early results with immunosuppression using rabbit antithymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients. Liver Transpl 2004; 10:404-407. (Pubitemid 38380315)
67. De Ruvo N, Cucchetti A, Lauro A, et al. Preliminary results of a 'prope' tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation. Transplantation 2005; 80:8-12. (Pubitemid 40980888)
68. Horton PJ, Tchervenkov J, Barkun JS, et al. Antithymocyte globulin induction therapy in hepatitis C-positive liver transplant recipients. J Gastrointest Surg 2005; 9:896-902. (Pubitemid 41224282)
69. Nair S, Loss GE, Cohen AJ, et al. Induction with rabbit antithymocyte globulin versus induction with corticosteroids in liver transplantation: impact of recurrent hepatitis C virus infection. Transplantation 2006; 81:620-622.
70. Uemura T, Schaefer E, Hollenbeak CS, et al. Outcome of induction immunosuppression for liver transplantation comparing antithymocyte globulin, daclizumab, and corticosteroid. Transpl Int 2011; 24:640-650.
71. Tzakis AG, Tryphonopoulos P, Kato T, et al. Preliminary experience with alemtuzumab (campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation 2004; 77:1209-1214. (Pubitemid 38580299)
72. Tryphonopoulos P, Madariaga JR, Kato T, et al. The impact of campath 1H induction in adult liver allotransplantation. Transplant Proc 2005; 37:1203-1204. (Pubitemid 40590836)